Highlights
- Lupin shares rose nearly 1% and touched a fresh 52-week high during early trade.
- The stock has delivered over 30% returns in one year, outperforming the Nifty Midcap 50.
- The company reported audited standalone and consolidated FY26 March quarter financial results in May.
Lupin Ltd. (NSE:LUPIN) traded higher during the morning session on July 8, with the stock rising 0.88% to INR 2,512.00. The stock opened at INR 2,492.50 and climbed to an intraday high of INR 2,526.90, which also marked its new 52-week high.
The session low remained at the opening price of INR 2,492.50. Lupin had settled at INR 2,490.20 in the previous session, while the volume-weighted average price (VWAP) stood at INR 2,514.03.
Trading Activity and Market Snapshot
Approximately 1.74 lakh shares were traded during the session, with a traded value of around INR 43.79 crore. The order book reflected 42.19% buy quantity against 57.81% sell quantity, indicating relatively higher sell orders despite the stock trading in positive territory.
Lupin's total market capitalisation stood at INR 1.15 lakh crore, while its free-float market capitalisation was INR 60,804.74 crore. The pharmaceutical company is part of the Nifty Midcap 50 index and continues to trade actively under the EQ series.
Stock Performance Across Timeframes
Lupin has delivered positive returns across most investment horizons. The stock has gained 4.65% over the past week and 11.29% over the last month, outperforming the Nifty Midcap 50, which returned 0.37% and 4.36%, respectively.
On a year-to-date basis, Lupin has advanced 19.32%, significantly ahead of the benchmark index's gain of 2.53%.
Over the past year, the stock has returned 30.53%, compared with 6.00% for the Nifty Midcap 50. The three-year return stands at 178.59%, while the five-year return is 120.07%.
Source: Analysis by Kalkine
FY26 March Quarter Financial Results
For the quarter ended March 31, 2026, Lupin reported consolidated total income of INR 7,61,537 lakh. Consolidated profit before tax stood at INR 1,92,800 lakh, while net profit was INR 1,46,867 lakh. Consolidated earnings per share (EPS) came in at INR 31.96.
On a standalone basis, total income was INR 5,32,343 lakh. Profit before tax was INR 2,60,235 lakh, while net profit stood at INR 2,16,369 lakh. Standalone EPS for the quarter was INR 47.35. The company released its audited consolidated financial results on May 7, 2026, followed by standalone financial results on May 8, 2026.
Valuation and Trading Metrics
Lupin is trading at a symbol P/E ratio of 21.26, while the adjusted P/E stands at 19.56. The stock has traded within a 52-week range of INR 1,836.80 to INR 2,526.90, with the latest session establishing a new 52-week high.
Daily volatility stands at 1.45%, while annualised volatility is 27.70%. The applicable margin rate is 12.57%, and the deliverable quantity accounted for 51.05% of traded volume.
Key Risks
- Regulatory observations could affect product approvals and operations.
- Currency fluctuations may influence overseas earnings.
- Pricing pressure in key pharmaceutical markets may impact margins.
- Competition from generic drug manufacturers could affect market share.
Summary
Lupin shares traded higher on July 8, gaining nearly 1% and touching a fresh 52-week high of INR 2,526.90 during the session. The pharmaceutical stock has outperformed the Nifty Midcap 50 across one-month, year-to-date and one-year periods. The company also reported audited standalone and consolidated financial results for the March 2026 quarter, reflecting profitability across both reporting segments.
FAQs
Q: What was Lupin's share price on July 8, 2026?
A: Lupin traded at INR 2,512.00, up 0.88% from the previous closing price during the morning session.
Q: Why is Lupin's 52-week high significant?
A: The stock touched a fresh 52-week high of INR 2,526.90, reflecting its highest traded level over the past year.
Q: What was Lupin's consolidated EPS for the March 2026 quarter?
A: Lupin reported consolidated earnings per share of INR 31.96 for the quarter ended March 31, 2026.